Compare AHG & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AHG | IRWD |
|---|---|---|
| Founded | 2013 | 1998 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 757.9M | 741.8M |
| IPO Year | N/A | 2010 |
| Metric | AHG | IRWD |
|---|---|---|
| Price | $1.44 | $4.57 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $3.68 |
| AVG Volume (30 Days) | 8.7K | ★ 2.7M |
| Earning Date | 08-14-2025 | 02-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.18 |
| Revenue | $14,842,253.00 | ★ $338,987,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $37.22 |
| P/E Ratio | ★ N/A | $25.07 |
| Revenue Growth | ★ 512.09 | N/A |
| 52 Week Low | $0.83 | $0.53 |
| 52 Week High | $2.10 | $5.78 |
| Indicator | AHG | IRWD |
|---|---|---|
| Relative Strength Index (RSI) | 48.25 | 51.38 |
| Support Level | $1.37 | $4.42 |
| Resistance Level | $1.48 | $4.91 |
| Average True Range (ATR) | 0.12 | 0.32 |
| MACD | -0.01 | -0.09 |
| Stochastic Oscillator | 40.70 | 33.49 |
Akso Health Group is a social e-commerce platform based in China. The company collaborates with domestic e-commerce platforms and offers users a wide selection of high-quality and affordable products on its social e-commerce platform. It generates majority of the revenues from sale of medical devices business.
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.